首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1922471

日本生物製药市场报告：按原料、产品、疾病、产量和地区划分（2026-2034年）

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年，日本生物製药市场规模达611亿美元。展望未来，IMARC集团预测，到2034年，该市场规模将达到1,635亿美元，2026年至2034年的复合年增长率（CAGR）为11.55%。推动市场成长的主要因素包括：对精准医疗方法的需求不断增长、对罕见疾病治疗的日益重视，以及癌症、类风湿性关节炎、多发性硬化症和慢性发炎性疾病等慢性复杂疾病盛行率的上升。

生物製剂涵盖范围广泛，包括单株抗体、疫苗、基因疗法和细胞疗法等。它们源自于细胞、蛋白质、基因和组织等生物来源成分。与透过化学方法合成的传统化学药物不同，生物製剂采用生物技术手段生产。生物製剂透过与体内特定标靶相互作用发挥治疗作用。它们以高度特异性和疗效着称，且副作用通常少于传统药物。生物製剂能够刺激免疫系统并诱导免疫反应，而不会引起疾病，有助于人体抵抗各种病毒和细菌的侵害。它们可以根据患者疾病的特定遗传或分子特征进行定制，从而实现个人化治疗。生物製剂能够促进组织再生和创伤治疗，且副作用少于传统化学药物。它们透过增强人体对癌细胞的免疫反应来帮助治疗某些类型的癌症。它们有助于解决影响弱势群体的罕见疾病和孤儿病问题。生物製剂可用于治疗、预防和控制多种疾病和病症。由于生物製剂能够有效控制症状、延缓疾病进展，进而改善患者的生活质量，因此日本对生物製剂的需求不断增长。

日本生物製药市场趋势：

目前，癌症、类风湿性关节炎、多发性硬化症和慢性发炎性疾病等慢性复杂疾病的日益普遍是推动日本市场成长的主要因素之一。此外，生物製药的广泛应用降低了住院的频率和严重程度，从而推动了日本国内市场的成长。精准医疗需求的不断成长也为市场带来了积极的前景。同时，患者对生物製药益处（例如副作用减少、住院时间缩短和疗效持久）的认识不断提高，为日本的行业投资者提供了丰厚的成长机会。因此，癌症治疗中对免疫疗法和单株抗体的需求不断增长，对市场产生了积极影响。此外，生物生产方法的创新使得生物製药的生产更具成本效益和效率，进一步促进了市场成长。同时，日本生物製药相关临床试验数量的增加也推动了市场成长。此外，大众对罕见疾病治疗日益增长的兴趣也是推动市场成长的因素之一。生物技术和基因组学领域的技术进步正在促进新型生物製药的发现和开发，进一步支持日本市场的成长。

本报告解答的关键问题

日本生物製药市场迄今的发展趋势及未来几年的展望
新冠疫情对日本生物製药市场产生了哪些影响？
日本生物製药市场依供应来源划分是怎样的？
日本生物製药市场依产品分類的组成是什么？
日本生物製药市场依疾病分類的组成是什么？
根据生产方法，日本生物製药市场的市场组成是怎样的？
日本生物製药市场价值链的不同阶段有哪些？
日本生物製药市场的主要驱动因素和挑战是什么？
日本生物製药市场的结构是怎么样的？主要参与者有哪些？
日本生物製药市场竞争有多激烈？

Japan biologics market size reached USD 61.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 163.5 Billion by 2034, exhibiting a growth rate (CAGR) of 11.55 % during 2026-2034. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Access the full market insights report Request Sample

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

JAPAN BIOLOGICS MARKET TRENDS:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

JAPAN BIOLOGICS MARKET SEGMENTATION:

Source Insights:

To get detailed segment analysis of this market Request Sample
Microbial
Mammalian
Others
Microbial
Mammalian
Others

Product Insights:

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others
Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others

Disease Insights:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others
Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

Manufacturing Insights:

Outsourced
In-House
Outsourced
In-House

Regional Insights:

To get detailed regional analysis of this market Request Sample
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT
How has the Japan biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan biologics market?
What is the breakup of the Japan biologics market on the basis of source?
What is the breakup of the Japan biologics market on the basis of product?
What is the breakup of the Japan biologics market on the basis of disease?
What is the breakup of the Japan biologics market on the basis of manufacturing?
What are the various stages in the value chain of the Japan biologics market?
What are the key driving factors and challenges in the Japan biologics?
What is the structure of the Japan biologics market and who are the key players?
What is the degree of competition in the Japan biologics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Biologics Market - Breakup by Source

6.1 Microbial
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Mammalian
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Others
- 6.3.1 Historical and Current Market Trends (2020-2025)
- 6.3.2 Market Forecast (2026-2034)

7 Japan Biologics Market - Breakup by Product

7.1 Monoclonal Antibodies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Vaccines
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Recombinant Proteins
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Antisense, RNAi and Molecular Therapy
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2020-2025)
- 7.5.2 Market Forecast (2026-2034)

8 Japan Biologics Market - Breakup by Disease

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Immunological Disorders
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Cardiovascular Disorders
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Hematological Disorders
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Forecast (2026-2034)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2020-2025)
- 8.5.2 Market Forecast (2026-2034)

9 Japan Biologics Market - Breakup by Manufacturing

9.1 Outsourced
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Forecast (2026-2034)
9.2 In-House
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Forecast (2026-2034)

10 Japan Biologics Market - Breakup by Region

10.1 Kanto Region
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2020-2025)
- 10.1.3 Market Breakup by Source
- 10.1.4 Market Breakup by Product
- 10.1.5 Market Breakup by Disease
- 10.1.6 Market Breakup by Manufacturing
- 10.1.7 Key Players
- 10.1.8 Market Forecast (2026-2034)
10.2 Kansai/Kinki Region
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Breakup by Source
- 10.2.4 Market Breakup by Product
- 10.2.5 Market Breakup by Disease
- 10.2.6 Market Breakup by Manufacturing
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2026-2034)
10.3 Central/ Chubu Region
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2020-2025)
- 10.3.3 Market Breakup by Source
- 10.3.4 Market Breakup by Product
- 10.3.5 Market Breakup by Disease
- 10.3.6 Market Breakup by Manufacturing
- 10.3.7 Key Players
- 10.3.8 Market Forecast (2026-2034)
10.4 Kyushu-Okinawa Region
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2020-2025)
- 10.4.3 Market Breakup by Source
- 10.4.4 Market Breakup by Product
- 10.4.5 Market Breakup by Disease
- 10.4.6 Market Breakup by Manufacturing
- 10.4.7 Key Players
- 10.4.8 Market Forecast (2026-2034)
10.5 Tohoku Region
- 10.5.1 Overview
- 10.5.2 Historical and Current Market Trends (2020-2025)
- 10.5.3 Market Breakup by Source
- 10.5.4 Market Breakup by Product
- 10.5.5 Market Breakup by Disease
- 10.5.6 Market Breakup by Manufacturing
- 10.5.7 Key Players
- 10.5.8 Market Forecast (2026-2034)
10.6 Chugoku Region
- 10.6.1 Overview
- 10.6.2 Historical and Current Market Trends (2020-2025)
- 10.6.3 Market Breakup by Source
- 10.6.4 Market Breakup by Product
- 10.6.5 Market Breakup by Disease
- 10.6.6 Market Breakup by Manufacturing
- 10.6.7 Key Players
- 10.6.8 Market Forecast (2026-2034)
10.7 Hokkaido Region
- 10.7.1 Overview
- 10.7.2 Historical and Current Market Trends (2020-2025)
- 10.7.3 Market Breakup by Source
- 10.7.4 Market Breakup by Product
- 10.7.5 Market Breakup by Disease
- 10.7.6 Market Breakup by Manufacturing
- 10.7.7 Key Players
- 10.7.8 Market Forecast (2026-2034)
10.8 Shikoku Region
- 10.8.1 Overview
- 10.8.2 Historical and Current Market Trends (2020-2025)
- 10.8.3 Market Breakup by Source
- 10.8.4 Market Breakup by Product
- 10.8.5 Market Breakup by Disease
- 10.8.6 Market Breakup by Manufacturing
- 10.8.7 Key Players
- 10.8.8 Market Forecast (2026-2034)

11 Japan Biologics Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Biologics Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis

14 Appendix

02-2729-4219

+886-2-2729-4219

License/价格

日本生物製药市场报告：按原料、产品、疾病、产量和地区划分（2026-2034年）

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2026-2034

日本生物製药市场趋势：

本报告解答的关键问题

目录

第一章：序言

第二章：调查范围与调查方法

第三章执行摘要

第四章：日本生物製药市场－引言

第五章 日本生物製药市场概述

第六章 日本生物製药市场－依原料细分

第七章 日本生物製药市场－依产品细分

第八章：日本生物製药市场－依疾病分类

第九章：日本生物製药市场－依生产方法细分

第十章：日本生物製药市场：依地区划分

第十一章：日本生物製药市场：竞争格局

第十二章主要企业概况

第十三章：日本生物製药市场：产业分析

第十四章附录